Scientific publications
Revisiting Interleukin-12 as a Cancer Immunotherapy Agent
Jun 15, 2018
| Magazine: Clinical Cancer Research
Pedro Berraondo, Iñaki Etxeberria, Mariano Ponz-Sarvise, Ignacio Melero
Abstract
IL12 antitumor activities are mediated by the activation of T and natural killer (NK) lymphocytes to produce IFNγ. Systemically, recombinant IL12 has a narrow therapeutic window that favors local delivery, for instance, by gene therapy approaches. IL12 is a powerful partner in immunotherapy combinations with checkpoint inhibitors and adoptive T-cell transfer.
CITATION Clin Cancer Res. 2018 Jun 15;24(12):2716-2718. doi: 10.1158/1078-0432.CCR-18-0381. Epub 2018 Mar 16.
